Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: Contribution of gastrointestinal infections to autoimmunity

Journal of Autoimmunity

Volumn 16, Issue 3, 2001, Pages 241-256

  Moran, A P ^a   Prendergast, M M ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Anti ganglioside antibodies; Atrophic gastritis; Autoimmunity; Campylobacter jejuni; Guillain Barr syndrome; Helicobacter pylori; Lewis antigens; Lipopolysaccharides; Molecular mimicry

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; BLOOD GROUP ANTIGEN; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; PROTON PUMP;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ATROPHIC GASTRITIS; AUTOIMMUNITY; BLOOD GROUP LEWIS SYSTEM; CAMPYLOBACTER JEJUNI; CONFERENCE PAPER; GASTROINTESTINAL INFECTION; GUILLAIN BARRE SYNDROME; HELICOBACTER PYLORI; IMMUNE RESPONSE; MOLECULAR MIMICRY; NERVE INJURY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STRAIN DIFFERENCE; STRUCTURE ANALYSIS; T LYMPHOCYTE ACTIVATION;

EID: 0034984992     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0490     Document Type: Conference Paper

References (175)

1. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations
2. Campylobacter infections in developing countries
3. Association between Campylobacter infection and Guillain-Barré syndrome
4. Campylobacter species and Guillain-Barré syndrome
5. Pathogenesis of Guillain-Barré syndrome
6. Molecular mimicry of host structures by bacterial lipopolysaccharide and its contribution to disease
7. The immunopathogenesis of Miller Fisher syndrome
8. Epidemiology of H. pylori in Western countries
9. Helicobacter pylori
10. Classification principles and genetics of chronic gastritis
11. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment
12. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity
13. Molecular mimicry of host structures by lipopolysaccharides of Campylobacter and Helicobacter spp.: Implications in pathogenesis
14. Biochemistry and cell biology of bacterial endotoxins
15. Cell surface characteristics of Helicobacter pylori
16. Structural and antigenic properties of lipopolysaccharide from serotype reference strains of Campylobacter jejuni
17. Serotyping of Campylobacter jejuni based on heat-stable antigens: Relevance, molecular basis and implications in pathogenesis
18. Molecular structure of bacterial endotoxin in relation to bioactivity
19. The structure of lipopolysaccharides of Gram-negative bacteria. III The structure of O-antigens: A review
20. The spectrum and pathogenesis of antibody-mediated neuropathies
21. Antibodies to glycoconjugates in neuropathy and motor-neuron disease
22. Serum antibodies to gangliosides in Guillain-Barré syndrome
23. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies
24. 1 antibodies following Campylobacter enteritis
25. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome
26. 1 IgA antibodies in Guillain-Barré syndrome
27. 1 antibodies in patients with Guillain-Barré syndrome
28. A randomized trial comparing intravenous globulin and plasma exchange in Guillain-Barré syndrome
29. 1 antibodies
30. 1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome
31. 1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: Correlations and prognosis
32. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders
33. Autoantibodies to peripheral nerve glycosphingolipids SPG, SPLG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy
34. 1α
35. 1b in Guillain-Barré syndrome subsequent to Campylobacter jejuni
36. 1b is a new member of antigen for serum antibody in Guillain-Barré syndrome
37. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom
38. 1a is a target molecule for serum antibody in Guillain-Barré syndrome
39. 1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome
40. 1a antibodies
41. 1a: Relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China
42. 1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies
43. 1b ganglioside
44. 1b antibody in Fisher's syndrome
45. 1b antibody
46. 1a gangliosides
47. 1b antibodies in Guillain-Barré syndrome
48. 1b antibodies in peripheral neuropathy
49. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni in Guillain-Barré syndrome
50. Bovine gangliosides and acute motor polyneuropathy
51. Acute axonal Guillain-Barré syndrome with IgG antibody against motor axons following parenteral gangliosides
52. Antibodies to glycoconjugates in neurological disease
53. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire
54. Autoimmunity and autoimmune diseases
55. Gangliosides and bacterial toxins in Guillain-Barré syndrome
56. 1b antibodies in Miller Fisher syndrome
57. A somatically mutated human antiganglioside antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18
58. Structure and specificity of antiganglioside antibodies associated with motor neuropathies
59. 1 antibodies cloned from motor neuropathy patients demonstrates diverse variable region gene usage with extensive somatic mutation
60. 1b are antigens for IgM M-protein in a patient with motor neuron disease
61. 1 antibodies, and multifocal motor conduction block
62. 1 and Gal(β1-3) GalNAc antigenic determinants in peripheral nerve
63. 1 ganglioside antibodies
64. Localisation of neural epitopes that bind to IgM monoclonal autoantibodies (M-proteins) from two patients with motor neuron disease
65. Acute conduction block in vitro following exposure to antiganglioside sera
66. The pattern of antiganglioside antibody reactivities producing myelinated nerve conduction block in vitro
67. + currents in isolated rat myelinated nerve fibres
68. 1 antibodies
69. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice
70. Demyelinative conduction block produced by intraneural injection of human Guillain-Barré serum into rat sciatic nerve
71. Passive transfer studies in Guillain-Barré polyneuropathy
72. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome
73. Demyelination induced by serum from patients with Guillain-Barré syndrome
74. 1 antibodies on saltatory conduction and transmembrane currents in single motor axons
75. 1 IgG or IgM to induce conduction block following intraneural transfer
76. Antibody of patients with Guillain-Barré syndrome mediates complement dependent cytolysis of rat Schwann cells: Susceptibility to cytolysis reflects Schwann cell phenotype
77. Effects of Guillain-Barré sera containing antibodies against glycolipids in cultures of rat Schwann cells and sensory neurons
78. 1 antibodies can block neuronal voltage-gated sodium channels
79. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro
80. Immune-mediated peripheral neuropathies and voltage-gated sodium channels
81. Generation of high titer, high affinity monoclonal IgG anti-ganglioside antibodies in mice lacking complex gangliosides
82. 1b antibodies: Alpha-latrotoxin-like effects on motor end plates
83. Neuromuscular blockade by immunoglobulin G from patients with Miller Fisher syndrome
84. Guillain-Barré syndrome associated with Campylobacter infection
85. Serotyping of Campylobacter jejuni and Campylobacter coli on the basis of thermostable antigens
86. Serological analysis of the heat-stable antigens involved in serotyping Campylobacter jejuni and Campylobacter coli
87. Characterization of cross-reacting serotypes of Campylobacter jejuni
88. Genetic and biochemical evidence of a Campylobacter jejuni capsular polysaccharide that accounts for Penner serotype specificity
89. Heat-stable serotyping antigens expressed by strains of Campylobacter jejuni are probably capsular and not long-chain lipopolysaccharide
90. Characterization of the antigens involved in serotyping strains of Campylobacter by passive haemagglutination
91. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain β-N-acetylglucosamine residues
92. Specific serotype of Campylobacter jejuni associated with Guillain-Barré syndrome
93. Guillain-Barré syndrome (GBS), acute motor axonal neuropathy and Campylobacter jejuni infection
94. Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain-Barré syndrome
95. 1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: Evidence of molecular mimicry
96. Campylobacter O:41 isolation in Guillain-Barré syndrome
97. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains
98. Association of serotype of Campylobacter jejuni with antiganglioside antibodies in Guillain-Barré syndrome and Fisher's syndrome
99. 3
100. 1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome
101. Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome
102. Campylobacter jejuni infection and Guillain-Barré syndrome
103. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies
104. Campylobacter neuropathy
105. In vivo effect of sera from patients with Guillain-Barré subgroups: An electrophysiological and histological study on rat nerves
106. Campylobacter jejuni isolates from Japanese patients with Guillain-Barré syndrome
107. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni infection and other identified infections
108. Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose
109. Ganglioside: Structure, isolation, and analysis
110. Chemical structure of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides
111. Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide
112. Lipopolysaccharides of Campylobacter jejuni serotype O:19. Structures of the core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome
113. 1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jejuni
114. 1 ganglioside
115. Lipopolysaccharides from a neuropathy-associated infection from Campylobacter jejuni serotype O:23
116. Lipopolysaccharide from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure
117. 1a epitope
118. Antibody crossreactivities between gangliosides and lipopolysaccharides of Campylobacter jejuni serotypes associated with Guillain-Barré syndrome
119. 1 ganglioside show diverse cross-reactivity with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barré syndrome
120. Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome
121. Ganglioside-like epitopes of lipopolysaccharide from Campylobacter jejuni (Pen 19) in three isolates from patients with Guillain-Barré syndrome
122. 1 in chronic neuropathies cross react with Campylobacter jejuni lipopolysaccharides
123. Experimental models of peripheral neuropathies
124. 1 ganglioside after immunization with lipopolysaccharides from Campylobacter jejuni
125. 1 antibodies by Campylobacter jejuni lipopolysaccharides
126. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations
127. 1 antibodies in rabbits
128. Experimental Campylobacter jejuni infection in the chicken: An animal model of axonal Guillain-Barré syndrome
129. O antigen chains in the lipopolysaccharides of Helicobacter pylori NCTC 11637
130. Lipopolysaccharide of the Helicobacter pylori type strain NCTC 11637 (ATCC 43504): Structure of the O antigen chain and core oligosaccharide regions
131. Lipopolysaccharides of Helicobacter pylori strains P466 and MO19: Structures of the O antigen and core oligosaccharide regions
132. Simultaneous expression of type 1 and type 2 Lewis blood group antigens by Helicobacter pylori lipopolysaccharides. Molecular mimicry between H. pylori lipopolysaccharides and human gastric epithelial cell surface glycoforms
133. Glycosylated N-acetyllactosamine O-antigen chain in the lipopolysaccharide from Helicobacter pylori strain UA861
134. Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide
135. Expression of the human cell surface glycoconjugates Lewis X and Lewis Y by Helicobacter pylori isolates is related to cagA status
136. Structural studies on lipopolysaccharides of serologically non-typable strains of Helicobacter pylori, AF1 and 007, expressing Lewis antigenic determinants
137. Mimicry of blood group antigen A by Helicobacter mustelae and Helicobacter pylori
138. Structure of an atypical O-antigen polysaccharide of Helicobacter pylori containing a novel monosaccharide 3-C-methyl-D-mannose
139. Lipopolysaccharides of serologically non-typable strains of Helicobacter pylori
140. Lipopolysaccharide structures of Helicobacter pylori genomic strains 26695 and J99, mouse model H. pylori Sydney strain, H. pylori P466 carrying sialyl-Lewis X, and H. pylori UA915 expressing Lewis B. Classification of H. pylori lipopolysaccharides into glycotype families
141. x blood group antigens in human gastric carcinoma and in normal gastric tissue
142. Pathogenic properties of Helicobacter pylori
143. Lack of correlation between Lewis antigen expression by Helicobacter pylori and gastric epithelial cells in infected patients
144. Relationship of blood group determinants on Helicobacter pylori lipopolysaccharide with host phenotype and inflammatory response
145. Lack of a relationship between Lewis antigen expression and cag A, CagA, vacA and VacA status of Irish Helicobacter pylori isolates
146. A relationship between the expression of high molecular weight lipopolysaccharides by Helicobacter pylori and colonising ability in mice
147. The effect of galE gene inactivation on lipopolysaccharide profile of Helicobacter pylori
148. The role of the lipopolysaccharide in adhesion of Helicobacter pylori to gastric mucosa
149. Role of adherence in interleukin-8 induction in Helicobacter pylori-associated gastritis
150. Molecular mimicry between Helicobacter pylori and the host
151. Bugs on trial: The case of Helicobacter pylori and autoimmunity
152. Helicobacter pylori infection induce antibodies cross-reacting with human gastric mucosa
153. Antigastric autoantibodies in Helicobacter pylori infection: Implications of the histological and clinical parameters of gastritis
154. Helicobacter pylori expresses complex surface carbohydrate, Lewis X
155. +-adenosine triphosphate of the stomach
156. Poly-N-acetyllactosamine-specific tomato lectin binding 60-90 x Mr membrane glycoprotein
157. Gastric parietal cell antigens of 60-90, 92, and 100-120 kDa associated with autoimmune gastritis and pernicious anaemia. Role of N-glycans in the structure and antigenicity of the 60-90 kDa component
158. Positive correlation between H,K-adenosine triphosphate autoantibodies and Helicobacter pylori antibodies in patients with pernicious anaemia
159. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis
160. Epithelial attachment alters the outcome of Helicobacter pylori infection
161. Evidence of novel pathogenic pathways for the formation of antigastric autoantibodies in Helicobacter pylori gastritis
162. Lewis antigen expression on outer membrane vesicles of Helicobacter pylori: Implications for virulence
163. Effect of host Lewis blood group antigen expression on Helicobacter pylori colonisation density and the consequent inflammatory response
164. Monoclonal antibodies that recognise lacto-N-fuco-pentose III (CD15) react with the adhesion-promoting glycoprotein family (LFA-1/Nmac-1/gp 150,95) and CR1 on human neutrophils
165. x) and CD15-expressing carcinoembryonic antigen-related glycoprotein NCA-160
166. Monoclonal antibodies to the carbohydrate structure Lewis X stimulate the adhesive activity of leucocyte integrin CD11b/CD18 (CR3, Mac-1,α(m)β2) on human granulocytes
167. + T-cell subsets
168. Heterogeneity of cytokine secretion patterns and functions of helper T cells
169. x determinants on myeloid cells
170. Sialylation of lipooligosaccharide cores affects immunogenicity and serum resistance of C. jejuni
171. Serotype of Campylobacter jejuni, HLA, and the Guillain-Barré syndrome
172. Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects virulence
173. Phase variation in Helicobacter pylori lipopolysaccharide due to changes in the lengths of poly(C) tracts in α3-fucosyltransferase genes
174. Lewis antigens in Helicobacter pylori: Biosynthesis and phase variation
175. Molecular mimicry in Campylobacter jejuni lipopolysaccharides and the development of Guillain-Barré syndrome